Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Further Commits To Neuroscience With Prothena Pact

Executive Summary

It is a risky business but the biotech major is paying $150m upfront, and potentially hundreds of millions of dollars more, to work with Prothena and develop therapies targeted at proteins implicated in highly challenging neurodegenerative diseases such as Alzheimer's and ALS.

Advertisement

Related Content

Biopharma Quarterly Dealmaking Statistics, Q1 2018
Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group
Celgene's Terrie Curran On Building, Broadening The I&I Franchise
Deal Watch: Opportunity Knocks For Partnerships In Asia
Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline
More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS
Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
Neuroscience Reaches A New Inflection Point, Big Biotechs Say

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100607

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel